172 related articles for article (PubMed ID: 34531230)
21. Successful perinatal management of a woman with congenital factor XIII deficiency using recombinant factor XIII: A case report and literature review.
Ito Y; Tsuji S; Kasahara M; Tokoro S; Murakami T; Takayama H
J Obstet Gynaecol Res; 2024 Feb; 50(2):262-265. PubMed ID: 37875278
[TBL] [Abstract][Full Text] [Related]
22. Recombinant FXIII (rFXIII-A2) Prophylaxis Prevents Bleeding and Allows for Surgery in Patients with Congenital FXIII A-Subunit Deficiency.
Carcao M; Altisent C; Castaman G; Fukutake K; Kerlin BA; Kessler C; Lassila R; Nugent D; Oldenburg J; Garly ML; Rosholm A; Inbal A
Thromb Haemost; 2018 Mar; 118(3):451-460. PubMed ID: 29448295
[TBL] [Abstract][Full Text] [Related]
23. Coagulation factor XIII deficiency. Diagnosis, prevalence and management of inherited and acquired forms.
Biswas A; Ivaskevicius V; Thomas A; Oldenburg J
Hamostaseologie; 2014; 34(2):160-6. PubMed ID: 24503678
[TBL] [Abstract][Full Text] [Related]
24. Reciprocal stabilization of coagulation factor XIII-A and -B subunits is a determinant of plasma FXIII concentration.
Byrnes JR; Lee T; Sharaby S; Campbell RA; Dobson DA; Holle LA; Luo M; Kangro K; Homeister JW; Aleman MM; Luyendyk JP; Kerlin BA; Dumond JB; Wolberg AS
Blood; 2024 Feb; 143(5):444-455. PubMed ID: 37883802
[TBL] [Abstract][Full Text] [Related]
25. Factor XIII deficiency management: a review of the literature.
Odame JE; Chan AK; Wu JK; Breakey VR
Blood Coagul Fibrinolysis; 2014 Apr; 25(3):199-205. PubMed ID: 24401950
[TBL] [Abstract][Full Text] [Related]
26. Minimal factor XIII activity level to prevent major spontaneous bleeds.
Menegatti M; Palla R; Boscarino M; Bucciarelli P; Muszbek L; Katona E; Makris M; Peyvandi F;
J Thromb Haemost; 2017 Sep; 15(9):1728-1736. PubMed ID: 28688221
[TBL] [Abstract][Full Text] [Related]
27. Free factor XIII activation peptide (fAP-FXIII) is a regulator of factor XIII activity via factor XIII-B.
Dodt J; Pasternack R; Seitz R; Volkers P
Br J Haematol; 2016 Feb; 172(3):452-60. PubMed ID: 26516704
[TBL] [Abstract][Full Text] [Related]
28. Alloantibodies against the B subunit of plasma factor XIII developed in its congenital deficiency.
Wada H; Souri M; Matsumoto R; Sugihara T; Ichinose A
Thromb Haemost; 2013 Apr; 109(4):661-8. PubMed ID: 23407795
[TBL] [Abstract][Full Text] [Related]
29. Autoimmune factor XIII deficiency with unusual laboratory and clinical phenotype.
Bovet J; Hurják B; De Maistre E; Katona É; Pénzes K; Muszbek L
J Thromb Haemost; 2020 Jun; 18(6):1330-1334. PubMed ID: 32311817
[TBL] [Abstract][Full Text] [Related]
30. Congenital factor XIII deficiency in Switzerland: from the worldwide first case in 1960 to its molecular characterisation in 2005.
Schroeder V; Durrer D; Meili E; Schubiger G; Kohler HP
Swiss Med Wkly; 2007 May; 137(19-20):272-8. PubMed ID: 17594539
[TBL] [Abstract][Full Text] [Related]
31. Recombinant factor XIII: a safe and novel treatment for congenital factor XIII deficiency.
Inbal A; Oldenburg J; Carcao M; Rosholm A; Tehranchi R; Nugent D
Blood; 2012 May; 119(22):5111-7. PubMed ID: 22451421
[TBL] [Abstract][Full Text] [Related]
32. Acquired Factor XIII Inhibitor in Hospitalized and Perioperative Patients: A Systematic Review of Case Reports and Case Series.
Tone KJ; James TE; Fergusson DA; Tinmouth A; Tay J; Avey MT; Kilty S; Lalu MM
Transfus Med Rev; 2016 Jul; 30(3):123-31. PubMed ID: 27167905
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics and safety of plasma-derived factor XIII concentrate (human) in patients with congenital factor XIII deficiency.
Nugent DJ; Ashley C; García-Talavera J; Lo LC; Mehdi AS; Mangione A
Haemophilia; 2015 Jan; 21(1):95-101. PubMed ID: 25458735
[TBL] [Abstract][Full Text] [Related]
34. Safety and pharmacokinetics of recombinant factor XIII in healthy volunteers: a randomized, placebo-controlled, double-blind, multi-dose study.
Visich JE; Zuckerman LA; Butine MD; Gunewardena KA; Wild R; Morton KM; Reynolds TC
Thromb Haemost; 2005 Oct; 94(4):802-7. PubMed ID: 16270634
[TBL] [Abstract][Full Text] [Related]
35. An international collaborative study to assign value for Total Factor XIII-B Subunit Antigen to the WHO 1st International Standard for Factor XIII Plasma, (02/206): Communication from the ISTH SSC Subcommittee on Factor XIII and Fibrinogen.
Raut S; Katona É; Riches-Duit A; Coxon C; Muszbek L; Schroeder V; Rigsby P
J Thromb Haemost; 2022 Feb; 20(2):525-531. PubMed ID: 34784091
[TBL] [Abstract][Full Text] [Related]
36. Neoplasm-induced bleeding in inherited, heterozygous FXIII-A deficiency.
Ivaškevičius V; Goldmann G; Biswas A; Westhofen P; Thomas A; Marquardt N; Horneff S; Klein C; Rühl H; Pötzsch B; Oldenburg J
Hamostaseologie; 2015; 35 Suppl 1():S32-5. PubMed ID: 26540128
[TBL] [Abstract][Full Text] [Related]
37. Factor XIII deficiency: an update.
Schroeder V; Kohler HP
Semin Thromb Hemost; 2013 Sep; 39(6):632-41. PubMed ID: 23929307
[TBL] [Abstract][Full Text] [Related]
38. Acquired Factor Xiii Deficiency: An Uncommon But Easily Missed Cause Of Severe Bleeding.
Fogarty H; Byrne M; O’Connell NM; Ryan K; White B; O’Donnell JS; Lavin M
Ir Med J; 2018 May; 111(5):757. PubMed ID: 30489053
[TBL] [Abstract][Full Text] [Related]
39. Identification of a novel mutation in the factor XIII A subunit in a patient with inherited factor XIII deficiency.
Yan L; Wang T; Qiu J; Zhang X; Peng J; Fang Y; Sheng Z
Int J Hematol; 2023 Jul; 118(1):26-35. PubMed ID: 37059930
[TBL] [Abstract][Full Text] [Related]
40. A Unique Factor XIII Mutation in Southeastern Iran with an Unexpectedly High Prevalence: Khash Factor XIII.
Dorgalaleh A; Tabibian S; Shams M; Majid G; Naderi M; Casini A; Tavasoli B; Gheidishiran M; Daneshi M; Safa M
Semin Thromb Hemost; 2019 Feb; 45(1):43-49. PubMed ID: 30630205
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
